

RECEIVED
CENTRAL FAX CENTER

JUN 30 2006

PTO/SB/21 (09-04)


Approved for use through 07/31/2006. OMB 0651-0031


U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM (to be used for all correspondence after initial filing)	Application Number	10/664,639
	Filing Date	9/18/2006
	First Named Inventor	Stanley T. Crooke
	Art Unit	1635
	Examiner Name	Jane J. Zara
Total Number of Pages in This Submission	9	Attorney Docket Number CORE0027US

ENCLOSURES (Check all that apply)		
<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> After Allowance Communication to TC
<input type="checkbox"/> Preliminary Amendment	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s)	<input checked="" type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation <input type="checkbox"/> Change of Correspondence Address	<input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Terminal Disclaimer	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Request for Refund	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> CD, Number of CD(s) _____ <input type="checkbox"/> Landscape Table on CD	<input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): Petition to Correct Inventorship, Stmt Confirming No Deceptive Intent, Stmt from Assignee, Stmt under 37 CFR 3.73(b), Executed Declaration
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> Remarks	
<input type="checkbox"/> Reply to Missing Parts/Incomplete Application <input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT		
Firm Name	Isis Pharmaceuticals, Inc.	
Signature		
Printed name	Jodi L. Connolly, Ph.D.	
Date	06/30/2006	Reg. No. 54,044

CERTIFICATE OF TRANSMISSION/MAILING		
I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below:		
Signature		
Typed or printed name	Laura Eames	Date 6/30/2006

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Application No: 10/664,639

Attorney Docket No: CORE0027US

In re Application of:
Crooke et al.


Application No: 10/664,639

Filed: September 18, 2003

For: EFFICIENT REDUCTION OF TARGET RNA's BY SINGLE- AND
DOUBLE-STRANDED OLIGOMERIC COMPOUNDS

I certify that this correspondence is being facsimile
transmitted or is being deposited with the U.S. postal
Service as First Class mail in an envelope addressed to the
Commissioner for Patents, P.O. Box 1450, Alexandria, VA
22313-1450.

On 6/30/2006


Laura EarnsRECEIVED
CENTRAL FAX CENTER

JUN 30 2006

REQUEST TO CORRECT INVENTORSHIP

Pursuant to 37 C.F.R. §1.48(b) and 37 C.F.R. §1.48(c)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Applicants hereby petition, pursuant to 37 C.F.R. 1.48(b), to correct inventorship of the above-identified non-provisional application. The patent application as originally filed correctly named Timothy Vickers, Seongjoon Koo, C. Frank Bennett, Stanley T. Crooke, Nicholas M. Dean, and Brenda F. Baker as inventors. However, amendments and/or cancellation of the claims filed June 30, 2006 in response to the Restriction Requirement dated June 2, 2006, has resulted in a change in inventorship. Please remove Timothy Vickers, Seongjoon Koo, C. Frank Bennett, and Nicholas M. Dean as named inventors in this application. Applicants acknowledge these inventors' invention is no longer being claimed in the instant application.

In addition, Applicants hereby petition, pursuant to 37 C.F.R. §1.48(c), to have Thazha P. Prakash added as a named inventor to the above-identified non-provisional application. The addition of Thazha P. Prakash is necessitated by the claim amendments filed May 25, 2006, which added claims to subject matter disclosed in the application as originally filed, but previously unclaimed. Applicants submit that the inventorship error occurred without deceptive intent on the part of the omitted inventor.


Application No: 10/664,639

Attorney Docket No: CORE0027US

Included herewith is a Statement Confirming No Deceptive Intent on the part of the added inventor, a Statement from the Assignee pursuant to 37 C.F.R. §1.48(c), and a Statement Under 37 CFR 3.73(b). Also included herewith is a Declaration pursuant to 37 C.F.R. §1.63 executed by each actual inventor.

The Director is hereby authorized to charge the processing fee set forth in 37 C.F.R. § 1.17(i) and any other fees due with the filing of this paper to the Isis Pharmaceuticals, Inc., Deposit Account 50-0252.

Respectfully submitted,

Dated: 06/30/2006

Jodi L. Connolly, Ph.D.

Registration No: 54,044
Isis Pharmaceuticals, Inc.
1896 Rutherford Rd.
Carlsbad, CA 92008-7208

Application No: 10/664,639

Attorney Docket No: CORE0027US

In re Application of:
Crooke et al.

RECEIVED
CENTRAL FAX CENTER
JUN 30 2006

Application No: 10/664,639

Filed: September 18, 2003

For: EFFICIENT REDUCTION OF TARGET RNA's BY SINGLE- AND
DOUBLE-STRANDED OLIGOMERIC COMPOUNDS


STATEMENT CONFIRMING NO DECEPTIVE INTENT
Pursuant to 37 C.F.R. §1.48(c)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

I, Thazha P. Prakash, hereby state that I am to be added as an inventor to United States Patent Application Serial No. 10/664,639, along with fellow inventors Stanley T. Crooke, and Brenda F. Baker, as a result of amendments to the claims filed May 25, 2006. I further state that the error in omitting me from being listed as an inventor occurred without deceptive intent on my part.

Signed this 29 day of June, 2006 by



Thazha P. Prakash

Application No: 10/664,639

Attorney Docket No: CORE0027US

In re Application of:
Crooke et al.

Application No: 10/664,639

Filed: September 18, 2003

For: EFFICIENT REDUCTION OF TARGET RNA's BY SINGLE- AND
DOUBLE-STRANDED OLIGOMERIC COMPOUNDS**RECEIVED**
CENTRAL FAX CENTER
JUN 30 2006STATEMENT FROM ASSIGNEE

Pursuant to 37 C.F.R. §1.48(c)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

I hereby assert that I am authorized to act on behalf of the assignee, Isis Pharmaceuticals Inc., 1896 Rutherford Road, Carlsbad, California, 92008, the owner of the entire right, title and interest in U.S. Patent Application No. 10/664,639 (see attached Statement under 37 C.F.R. § 3.73(b)). I further hereby assert that the assignee agrees to the inventorship change in U.S. Patent Application No. 10/664,639 to the following inventive entity:

Stanley T. Crooke, Brenda F. Baker, and Thazha P. Prakash.

Signed this 24th day of June, 2006 byGrant Bryce
Vice President, Legal and
General Counsel
Isis Pharmaceuticals, Inc.
1896 Rutherford Rd.
Carlsbad, CA 92008-7208

PTO/SB/96 (09-04)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

STATEMENT UNDER 37 CFR 3.73(b)Applicant/Patent Owner: Isis Pharmaceuticals, Inc.Application No./Patent No.: 10/664,839Filed/Issue Date: 9/18/2003Entitled: EFFICIENT REDUCTION OF TARGET RNA'S BY SINGLE- AND DOUBLE-STRANDED OLIGOMERIC COMPOUNDSIsis Pharmaceuticals, Inc.

(Name of Assignee)

a Corporation

(Type of Assignee, e.g., corporation, partnership, university, government agency, etc.)

states that it is:

1. ☒ the assignee of the entire right, title, and interest; or
2. ☐ an assignee of less than the entire right, title and interest.
The extent (by percentage) of its ownership interest is _____ %

in the patent application/patent identified above by virtue of either:

- A. ☒ An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the United States Patent and Trademark Office at Reel 14414, Frame 0596, or for which a copy thereof is attached.

OR

- B. ☐ A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as shown below:

1. From: _____ To: _____
The document was recorded in the United States Patent and Trademark Office at Reel _____, Frame _____, or for which a copy thereof is attached.
2. From: _____ To: _____
The document was recorded in the United States Patent and Trademark Office at Reel _____, Frame _____, or for which a copy thereof is attached.
3. From: _____ To: _____
The document was recorded in the United States Patent and Trademark Office at Reel _____, Frame _____, or for which a copy thereof is attached.

☐ Additional documents in the chain of title are listed on a supplemental sheet.☐ Copies of assignments or other documents in the chain of title are attached.

(NOTE: A separate copy (i.e., a true copy of the original assignment document(s)) must be submitted to Assignment Division in accordance with 37 CFR Part 3, if the assignment is to be recorded in the records of the USPTO. See MPEP 302.08]

The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.



Signature

6/28/06

Date

Grantland E. Bryce

Printed or Typed Name

760-931-200

Telephone Number

Vice President, General and Legal Counsel

Title

This collection of information is required by 37 CFR 3.73(b). The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.